Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Prostate cancer screening: more harm than good?

M L Lefevre1

  • 1University of Missouri School of Medicine, Columbia, USA.

American Family Physician
|August 26, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Issues in implementing prenatal screening for cystic fibrosis: results of a working conference.

Genetics in medicine : official journal of the American College of Medical Genetics·2001
Same author

Urinary tract infections during pregnancy.

American family physician·2000
Same author

An investigation of social and class differences in very-low birth weight outcomes: a continuing public health concern.

Journal of health care finance·1999
Same author

Are resident physicians serving as primary care providers for managed care patients?

Family medicine·1997
Same author

Determinants of preterm delivery in low-risk pregnancies. The RADIUS Study Group.

Journal of clinical epidemiology·1996
Same author

Preterm labor: ACOG guidelines for care.

American family physician·1995
Same journal

For Post-stent Patients With Atherosclerotic Coronary Vascular Disease Who Are Taking an Anticoagulant, Adding Aspirin Worsens Outcomes.

American family physician·2026
Same journal

Nausea and Vomiting During Pregnancy.

American family physician·2026
Same journal

Metabolic Dysfunction-Associated Steatotic Liver Disease: Diagnosis and Management.

American family physician·2026
Same journal

Aerobic Exercise Is the Better Exercise Modality for Knee Osteoarthritis.

American family physician·2026
Same journal

Overscreening Leads to Overdiagnosis of MASLD.

American family physician·2026
Same journal

Type 2 Diabetes: Outpatient Insulin Management.

American family physician·2026
See all related articles

Routine prostate cancer screening using prostate-specific antigen (PSA) tests lacks strong evidence. It may detect non-aggressive cancers, leading to harmful treatments without proven mortality benefits.

Area of Science:

  • Urology
  • Oncology
  • Preventive Medicine

Background:

  • National medical organizations recommend routine prostate cancer screening for men over 50.
  • The serum prostate-specific antigen (PSA) assay is the primary screening tool.
  • Current recommendations are based on expert opinion rather than robust clinical evidence.

Purpose of the Study:

  • To critically evaluate the evidence supporting routine prostate-specific antigen (PSA) screening for prostate cancer.
  • To assess the benefits and harms of PSA screening in the context of established screening principles.
  • To highlight the need for high-quality evidence to guide clinical practice.

Main Methods:

  • Critical review of existing scientific literature and screening principles.

Related Experiment Videos

  • Analysis of data from prospective studies and randomized clinical trials.
  • Evaluation of the potential for overdiagnosis and overtreatment of indolent prostate cancer.

    • Main Results:

    • Limited evidence from prospective studies supports the routine use of PSA testing for prostate cancer screening.
    • PSA screening frequently identifies indolent, non-aggressive prostate cancers.
    • Treatments for detected cancers (radiation, prostatectomy) carry significant risks (incontinence, impotence) without proven mortality reduction.

    Conclusions:

    • The routine use of PSA screening for prostate cancer lacks sufficient evidence from prospective studies.
    • The potential harms of treatment for overdiagnosed cancers may outweigh the benefits.
    • Randomized clinical trials are urgently needed to establish the efficacy and safety of routine PSA screening.